+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Overactive Bladder Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023 - Product Image

Overactive Bladder Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023

  • ID: 4829002
  • Report
  • Region: Global
  • 157 pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Endo International Plc
  • KYORIN Holdings Inc.
  • Merck & Co. Inc.
  • Mylan NV
  • MORE
Global Overactive Bladder Therapeutics Market: About this market

The overactive bladder (OAB) therapeutics market analysis considers sales from anticholinergics. Beta-3 adrenergic agonists, and other OAB therapeutics. The analysis also considers the sales of overactive bladder therapeutics in Asia, Europe, North America, and ROW. In 2018, the anticholinergics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as increasing availability of branded drugs and rise in popularity of combination therapy will play a significant role in the anticholinergics segment to maintain its market position. Also, the global overactive bladder therapeutics market report looks at factors such as the increasing number of drug approvals, the advent of combination therapy, and strategic alliance. However, extensive use devices to treat OAB, side effects associated with OAB, and rising patent litigations may hamper the growth of the overactive bladder therapeutics industry over the forecast period.

Global Overactive Bladder Therapeutics Market: Overview

The advent of combination therapy

The launch of combination therapy offers patients an efficacious pharmacological regime which requires shorter duration for treatment and reduces the overall cost associated with medication treatment. Astellas was the first vendor to introduce a combination therapy, which exhibits higher efficacy with fewer side-effects. This advent of combination therapy will lead to the expansion of the global overactive bladder therapeutics market at a CAGR of almost 2% during the forecast period.

The advent of gene therapy

The treatment therapy available for OAB involves the use of small molecules, which helps in the relaxation of smooth muscles in the urinary bladder to control the emptying of the bladder. The medication therapy, which is used exerts its pharmacological effect by suppressing the overactivity of the detrusor muscle. The drugs used in the therapy are associated with certain side effects like dry mouth, constipation, blurred vision, and cognitive impairment. Thus, there is a need for the development of biological drugs targeting the gene and consequently improving bladder functioning. The ongoing research in this area is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of several major players, the global overactive bladder therapeutics market is moderately fragmented. The robust vendor analysis is designed to help clients improve their market position. This report provides a detailed analysis of several leading overactive bladder therapeutics manufacturers, that include AbbVie Inc., Astellas Pharma Inc., Camber Pharmaceuticals Inc., Endo International Plc., KYORIN Holdings Inc., Merck & Co. Inc., Mylan NV, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Teva Pharmaceutical Industries Ltd.

Also, the overactive bladder therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Endo International Plc
  • KYORIN Holdings Inc.
  • Merck & Co. Inc.
  • Mylan NV
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: PIPELINE LANDSCAPE

PART 07: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Anticholinergics - Market size and forecast 2018-2023
  • Beta-3 adrenergic agonists - Market size and forecast 2018-2023
  • Other OAB therapeutics - Market size and forecast 2018-2023
  • Market opportunity by product
PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS
  • Advent of gene therapy
  • Rising risk factors of OAB
  • Growing geriatric population
PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • Astellas Pharma, Inc.
  • Camber Pharmaceuticals Inc.
  • Endo International Plc
  • KYORIN Holdings Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Vendors: Key offerings
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Some key clinical trials in global OAB therapeutics market
Exhibit 19: Product - Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: Anticholinergics - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Anticholinergics - Year-over-year growth 2019-2023 (%)
Exhibit 23: Beta-3 adrenergic agonists - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Beta-3 adrenergic agonists - Year-over-year growth 2019-2023 (%)
Exhibit 25: Other OAB therapeutics - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Other OAB therapeutics - Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in North America
Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Europe
Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Asia
Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in ROW
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: AbbVie Inc. - Vendor overview
Exhibit 52: AbbVie Inc. - Business segments
Exhibit 53: AbbVie Inc. - Organizational developments
Exhibit 54: AbbVie Inc. - Geographic focus
Exhibit 55: AbbVie Inc. - Key offerings
Exhibit 56: AbbVie Inc. - Key customers
Exhibit 57: Astellas Pharma Inc. - Vendor overview
Exhibit 58: Astellas Pharma Inc. - Business segments
Exhibit 59: Astellas Pharma Inc. - Organizational developments
Exhibit 60: Astellas Pharma Inc. - Geographic focus
Exhibit 61: Astellas Pharma Inc. - Key offerings
Exhibit 62: Astellas Pharma Inc. - Key customers
Exhibit 63: Camber Pharmaceuticals Inc. - Vendor overview
Exhibit 64: Camber Pharmaceuticals Inc. - Business segments
Exhibit 65: Camber Pharmaceuticals Inc. - Organizational developments
Exhibit 66: Camber Pharmaceuticals Inc. - Key offerings
Exhibit 67: Camber Pharmaceuticals Inc. - Key customers
Exhibit 68: Endo International Plc - Vendor overview
Exhibit 69: Endo International Plc - Business segments
Exhibit 70: Endo International Plc - Organizational developments
Exhibit 71: Endo International Plc - Geographic focus
Exhibit 72: Endo International Plc - Segment focus
Exhibit 73: Endo International Plc - Key offerings
Exhibit 74: Endo International Plc - Key customers
Exhibit 75: KYORIN Holdings Inc. - Vendor overview
Exhibit 76: KYORIN Holdings Inc. - Business segments
Exhibit 77: KYORIN Holdings Inc. - Organizational developments
Exhibit 78: KYORIN Holdings Inc. - Geographic focus
Exhibit 79: KYORIN Holdings Inc. - Segment focus
Exhibit 80: KYORIN Holdings Inc. - Key offerings
Exhibit 81: KYORIN Holdings Inc. - Key customers
Exhibit 82: Merck & Co. Inc. - Vendor overview
Exhibit 83: Merck & Co. Inc. - Business segments
Exhibit 84: Merck & Co. Inc. - Organizational developments
Exhibit 85: Merck & Co. Inc. - Geographic focus
Exhibit 86: Merck & Co. Inc. - Segment focus
Exhibit 87: Merck & Co. Inc. - Key offerings
Exhibit 88: Merck & Co. Inc. - Key customers
Exhibit 89: Mylan NV - Vendor overview
Exhibit 90: Mylan NV - Product segments
Exhibit 91: Mylan NV - Organizational developments
Exhibit 92: Mylan NV - Geographic focus
Exhibit 93: Mylan NV - Segment focus
Exhibit 94: Mylan NV - Key offerings
Exhibit 95: Mylan NV - Key customers
Exhibit 96: Ono Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 97: Ono Pharmaceutical Co. Ltd. - Business segments
Exhibit 98: Ono Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 99: Ono Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 100: Ono Pharmaceutical Co. Ltd. - Key offerings
Exhibit 101: Ono Pharmaceutical Co. Ltd. - Key customers
Exhibit 102: Pfizer Inc. - Vendor overview
Exhibit 103: Pfizer Inc. - Business segments
Exhibit 104: Pfizer Inc. - Organizational developments
Exhibit 105: Pfizer Inc. - Geographic focus
Exhibit 106: Pfizer Inc. - Segment focus
Exhibit 107: Pfizer Inc. - Key offerings
Exhibit 108: Pfizer Inc. - Key customers
Exhibit 109: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 110: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 111: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 112: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 113: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 114: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 115: Validation techniques employed for market sizing
Exhibit 116: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Endo International Plc
  • KYORIN Holdings Inc.
  • Merck & Co. Inc.
  • Mylan NV
  • MORE
The following companies are recognised as the key players in the global overactive bladder therapeutics market: AbbVie Inc., Astellas Pharma Inc., Camber Pharmaceuticals Inc., Endo International Plc., KYORIN Holdings Inc., Merck & Co. Inc., Mylan NV, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Teva Pharmaceutical Industries Ltd.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the advent of gene therapy.”

According to the report, one of the major drivers for this market is the advent of combination therapy.

Further, the report states that one of the major factors hindering the growth of this market is the side effects associated with OAB.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Camber Pharmaceuticals Inc.
  • Endo International Plc
  • KYORIN Holdings Inc.
  • Merck & Co. Inc.
  • Mylan NV
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll